Launched July 2021 by British Patient Capital, BBB commercial subsidiary. £425m fund investing in growth-stage, R&D-intensive Life Sciences & Deeptech companies in UK. 9-person direct investment team. 18 portfolio companies; deployed £134m across 11 Life Sciences & 7 Deeptech firms. Crowded in £863m private sector capital. Regarded as high-quality investor; positive signal for company growth potential.
Investment Focus
Investment Thesis
Co-investment programme for growth-stage R&D-intensive companies in Life Sciences & Deeptech. Focus: quantum computing, semiconductors, climate tech, novel therapeutics. Check size: £5-10m per round. Minimum round size £20m, max 30% co-investment stake. Requires UK registered companies with majority R&D in UK. Avoids short time-to-market products. Co-invests with global tier-1 investors (Pfizer, Sanofi, Atomico, Northpond).
Interested in connecting?
Visit their website or reach out directly.